Immunologic Factor
daclizumab Audio
[ duh-klih-zoo-mab ]
Effect:
Decreased Cytokine Activity; Decreased Lymphocyte Activation; Decreased Lymphocyte Cell Production
May Prevent:
Graft vs Host Disease
May Treat:
Graft vs Host Disease; Multiple Sclerosis
Definitions related to daclizumab:
  • A monoclonal antibody that is being studied in the treatment of adult T-cell leukemia and in the treatment of cytopenia (low blood cell count).
    NCI Dictionary of Cancer Terms
    U.S. National Cancer Institute, 2021
  • A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.
    NCI Thesaurus
    U.S. National Cancer Institute, 2021
  • An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS.
    NLM Medical Subject Headings
    U.S. National Library of Medicine, 2021
Try this search on: Farlex, Merriam-Webster, Oxford Dictionary, or Wordnik

This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.